A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase II/III
Latest Information Update: 27 May 2015
At a glance
- Drugs Mecobalamin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 27 May 2015 Results presented at the 56th Annual Meeting of the Japanese Society of Neurology2, according to an Eisai media release.
- 27 May 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology1, according to an Eisai media release.
- 27 May 2015 According to an Eisai media release, the company has submitted an NDA for mecobalamin as a treatment for amyotrophic lateral sclerosis in Japan.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History